De novo Acute Myeloid Leukemia Associated with t(11;17)(q23;q25) and MLL-SEPT9 Rearrangement in an Elderly Patient: A Case Study and Review of the Literature

2011 ◽  
Vol 126 (4) ◽  
pp. 195-198 ◽  
Author(s):  
Sang-Guk Lee ◽  
Tae Sung Park ◽  
Seung Hwan Oh ◽  
Ji Chan Park ◽  
Young Joon Yang ◽  
...  
2010 ◽  
Vol 89 (12) ◽  
pp. 1283-1285
Author(s):  
Seung Hwan Oh ◽  
Tae Sung Park ◽  
So Young Kim ◽  
Gayoung Lim ◽  
Si Hyun Kim ◽  
...  

Diagnostics ◽  
2019 ◽  
Vol 9 (3) ◽  
pp. 84
Author(s):  
Carla Minoia ◽  
Vincenza de Fazio ◽  
Giovanni Scognamillo ◽  
Anna Scattone ◽  
Nicola Maggialetti ◽  
...  

Myeloid sarcoma (MS) represents a rare disease with an adverse clinical outcome for patients not candidate to acute myeloid leukemia (AML)-like chemotherapies. Here we present the case of an elderly patient affected by a bilateral breast localization of MS treated with the hypomethylating agent decitabine associated to radiotherapy. The association of the two treatment modalities has allowed an optimal and long-lasting disease control.


2021 ◽  
Vol 13 (1) ◽  
pp. e2021067
Author(s):  
Pouyan Kheirkhah ◽  
Ana M. Avila-Rodriguez ◽  
Bartlomiej Radzik ◽  
Carlos Murga-Zamalloa

Myeloid sarcomas can be detected in up to 30% of acute myeloid leukemia cases or occur de-novo without bone marrow involvement. The most frequent localization of myeloid sarcomas in the abdominal cavity is the small intestine, and gastric presentations are infrequent, frequently misdiagnosed, and a high level of suspicion should exist when the characteristic histomorphology features are present. The current review features a case report with gastric presentation of myeloid sarcoma in a patient with a diagnosis of acute myeloid leukemia with trisomy 8. In addition, a review of the literature of intestinal type myeloid sarcomas shows that less than 15% of these cases have been reported in the stomach. The most common molecular aberrancy detected in intestinal myeloid sarcomas is the fusion protein CBFB-MYH11. Review of several large studies demonstrates that the presence of myeloid sarcoma does not constitute an independent prognostic factor. The therapeutic approach will be tailored to the specific genetic abnormalities present, and systemic chemotherapy with hematopoietic stem cell transplant are the most efficient strategies.


2018 ◽  
Vol 6 ◽  
pp. 2050313X1775033 ◽  
Author(s):  
Shaimaa Elzamly ◽  
Santosh Chavali ◽  
Vijay Tonk ◽  
Sahil Tonk ◽  
Sumit Gaur ◽  
...  

Chromosomal rearrangement involving the KMT2A gene is one of the most common genetic alteration in acute myeloid leukemia. A total of 135 different KMT2A rearrangements have been identified, where 94 translocation partner genes are now characterized at the molecular level. Of these 94 translocation partner genes, 35 translocation partner genes occur recurrently, but only 9 specific gene fusions account for more than 90% of cases. Translocation of KMT2A with SEPT5 gene at 22q11.2 is rare, with few reported cases in the literature. In this report, we are presenting a case of KMT2A-SEPT5 fusion in de novo acute myeloid leukemia with t(11;22)(q23;q11.2) with a review of the literature.


Sign in / Sign up

Export Citation Format

Share Document